dihexa retracted paper controversy Good news! 📰⁠ ⁠ Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy Journal pulls paper by economist

Importantly, AOD-9604 does not bind to growth hormone receptors or stimulate IGF-1 production, which distinguishes it from full-length human growth hormone

[8] [9] This means that higher oral doses may be required in certain circumstances to achieve therapeutic effects

We showed that cirrhotic (an IGF-1 deficiency condition) rats had diminished amino acid and glucose intestinal absorption [114, 194, 195] and that IGF-1 replacement therapy was able to restore both alterations, suggesting a role of IGF-1 in the position of transporters [196]

A common pattern is a Myers Cocktail (which already has B12) once or twice a month, plus a quick standalone B12 shot in between if energy dips during a heavy stretch

The severity and duration of deficiency are primary determinantspatients with mild, recently developed deficiency typically respond more rapidly than those with longstanding, severe depletion

The concern isnt just that youll develop antibodies against the peptide itselfits that those antibodies might cross-react with your own endogenous proteins